We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.25 | 9.00 | 9.50 | 9.25 | 9.25 | 9.25 | 186,038 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.67 | 16.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/4/2018 15:59 | Very good key points in the interview I don't mind admitting I wasn't aware of...."Great technology can be screwed up by formulation. " Clearly more important than perhaps credited and gel's and lotion formulation to be tested. | elrico | |
17/4/2018 15:02 | New interview with Cath just out. 'Huge milestone' for SkinBioTherapeutics with cream formulation success | parob | |
17/4/2018 13:37 | Dr. Cath and her professor are a CLASS ACT they know their stuff inside-out..the development of the Gel and Lotion is just a formality. and an even larger resulting market along with many more opportunities. The ingredients of the cosmetic cream could be used perhaps in Sun Screen lotion providing protection from infections while giving the skin tone behind the tan more radiance. There are so many angles on these products it has to become a market leader in at least three sectors...imo. | bobalot | |
17/4/2018 09:43 | Impressive progress and this continues on quite a steep upward trend. Too early for an N4P effect or timing ahead of trials just about right? Either way happy to be in here at such low prices. | rathean | |
17/4/2018 09:18 | Human trials start in Q3 so they have just a few months to finalise the formulations for the Gel and Lotion....Dr. Cath looks very confident imo. Buying has now started at 11p: Skinbiotherapeutics PLC LON: SBTX 11,00 GBX +1,25 (12,82%) 17.04, 09:11 | bobalot | |
17/4/2018 09:14 | Yes so great news. So direct correlation of the protein in the skin to the amount of probiotic lysate extract in the cream. That clearly helps them accurately determine the level of dosing required to ensure the desired level of effectiveness of the product. Stability tests of the cream to follow. I guess another key test as you don't want the ingredients separating out in the bottle/transit etc. They are also effectively saying that the gel and lotion haven't quite reached their high levels of satisfaction yet. So more work to continue on refining those products. | toadhall1 | |
17/4/2018 08:01 | tHIS PART IS VERY INTERESTING shows a direct correlation, meaning the strength or effectiveness of the cream to enhance the skins barrier to infection can be controlled. And there will be three cosmetic products presented as a cream, gel and lotion....all very large target markets imo. The data further showed a direct correlation between the amount of SkinBiotix(R) within the cream and the level of the protein present. Work on creating skin lotion and gel formulations is ongoing. | bobalot | |
17/4/2018 07:09 | Confirmation of the formulation of creams may help to nudge this share in the right direction and become the beginning of a share price rerate given all the other good news in the pipeline.gla | nig1954 | |
16/4/2018 15:39 | Why is that Parob, has there been an Investor Show to-date that sparked a scintilla of interest in our beloved SBTX and OPTI? | owenmo | |
15/4/2018 16:38 | I'll be there and will feedback anything worthwhile | onedayrodders | |
15/4/2018 12:42 | SkinBioTherapeutics will be exhibiting at the UK Investor Show on Sat 21st April. Should hopefully drum up more investor interest in the company. | parob | |
15/4/2018 12:33 | The Role of the Skin Microbiome in Atopic Dermatitis (Eczema)hTTps://www. | parob | |
14/4/2018 10:55 | Elrico Great post and insight. My comments are more from a trading activity view. The last week or so we've started to see increased volume and an improvement on the share price performance. A close above 10p could see a decent run purely as it will have broken through ceiling. Some very nice buys been going through. I'm heavily in here already but am very tempted to add at these levels. I still think a commercial tie up could be done prior to the human trials so the Mn partner can have input into them. Let's not forget the dosage tests etc have been done in human skin samples already so what are the chances of success? At this current market cap it could be a real winner in time. S | shrewdmole | |
13/4/2018 16:12 | Elrico very good and informative views...SBTX is in the right pace at exactly the right time...The article published yesterday about developments in the Korean market underscores that view. Beyond beauty: Korean makeup provides 'cosmeceuticals' | bobalot | |
13/4/2018 15:44 | At the risk of falling into a trap...Paul - post 1486 is NOT a "Hybridan article" they are my personal views, with valuations of Hybridan as an illustration of SkinBiotix's huge potential. From memory, Hybridans valuation was prior the proof of concept, scientific validation, hence the high risk it put on SkinBiotix of failing. History now tells us the science works, thus we wait the final validation; human trials data. I also wanted to put across industry valuation (with assumptions all goes according to plan). I think we all agree SBTX has huge potential and by following the parent company's commercial footprint, SBTX will almost certainly multi-multi-bag from here in due course; but patience will be required. We must learn from OPTI's story, MN partners move at their pace, not at PI's pace. There are no further funding requirements, no marketing spend, and ongoing R&D done on the cheap via UoM labs, this all points to low PLC costs where partners pickup the marketing tab while SBTX reaps the royalties, etc. IMHO Cath has learned from SOH, which is why I suggest the MTA is a smart move and one that has the potential to speed up the commercial process by essentially getting the DD out of the way ahead of the human trial data. The question remains, is it J&J or another global corporate? The more I think about it, the more I'm inclined to think I am wrong in my first guess (J&J) because logic suggests J&J have been working very closely with SkinBiotix since June 2014, so I think it's a safe assumption there could be another global corporate in line to use SBTX IP. IF I am correct, this is a fantastic development for SBTX. | elrico | |
13/4/2018 14:56 | Coming from the master of repetitive info that would be quite funny if it wasn't so foolish. How is it old repetitive rubbish? Have i missed something? Don't you agree with the hybridan valuation? | paulhoodwinked | |
13/4/2018 14:50 | Indeed risky Holding firm here and at OPTI, should be great few years coming up | onedayrodders | |
13/4/2018 14:45 | If you like reading out-of date repetition then keep reading that rubbish. | bobalot | |
13/4/2018 14:34 | Opportunity to buy at IPO price or below has now gone imo. Next 12 months will see some great science translated in to commercial interest. Last RNS shows the corporate interest even before human studies. Science is clearly well sought after. People just need to be aware of how long it takes to build a business which relies on license deals. Patience will make a lot of money for people here and with Opti (even from 700% up from IPO 3 years ago... things are just beginning commercially over there) | riskybusiness1 | |
13/4/2018 14:12 | WOW instant arbitrage on current quote ! 9.50 offer 10.00 bid | onedayrodders | |
13/4/2018 13:03 | A small top up for me today. Surprised this hasn't moved up yet based on all the buying. Hoping 9.75p is the higher low going in. | parob |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions